Ondine Biomedical Reports Significant Reduction in SSI Rates

Ondine Biomedical Inc. has announced that the deployment of its Steriwave nasal decolonization technology at Mid Yorkshire Teaching NHS Trust resulted in a 71% reduction in surgical site infections (SSI) following elective knee and hip replacements. This marks the first use of Steriwave by the NHS in the UK.

A study conducted with the York Health Economics Consortium revealed that Steriwave not only decreases SSI rates, but it is also cost-effective, saving £2,869 and reducing hospital stays by 139 days in a standard cohort of 1,000 patients. The results showed that knee surgeries saw an SSI rate drop to zero.

Mid Yorkshire's implementation of Steriwave alongside standard care, including the use of octenidine gel and chlorhexidine body wash, demonstrated impressive patient and staff satisfaction. These promising outcomes highlight Steriwave's potential impact on healthcare practices globally.